FDA Approves First Medication for Obstructive Sleep Apnea
Español. Today, the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity, to be used in ...
FDA approves weight-loss drug Zepbound for obstructive sleep apnea
Dec 20, 2024 · For people with obstructive sleep apnea, Zepbound should be used with a reduced-calorie diet and increased physical activity, drugmaker Eli Lilly said. The US Food and Drug Administration on...
FDA Approves Zepbound for Obstructive Sleep Apnea - WebMD
Dec. 23, 2024 -- The FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
FDA approves weight loss drug Zepbound to treat obstructive sleep apnea
Dec 21, 2024 · Shots - Health News ... "This is a major step forward for patients with obstructive sleep apnea," said Dr. Sally Seymour, director of the Division of Pulmonology, Allergy, and Critical Care in the ...
FDA approves weight loss drug Zepbound for sleep apnea - NBC News
Dec 20, 2024 · The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in adults with obesity, the drugmaker Eli Lilly said Friday.
F.D.A. Approves Weight Loss Drug to Treat Obstructive Sleep Apnea
Dec 20, 2024 · The Food and Drug Administration on Friday approved the weight loss drug Zepbound to treat obstructive sleep apnea. It is the first prescription medication approved to treat the common sleep disorder.
FDA Approves First Medication for Obstructive Sleep Apnea - PR …
SILVER SPRING, Md., Dec. 20, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea...
FDA approves Eli Lilly’s obesity medication for obstructive sleep apnea
Dec 20, 2024 · The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.
News Release
INDIANAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound ® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. 1 Zepbound may help adults with moderate-to-severe ...
Study Identifies First Drug Therapy for Sleep Apnea - UC San Diego Health
Jun 21, 2024 · Researchers at University of California San Diego School of Medicine and international collaborators have led a worldwide, advanced study demonstrating the potential of tirzepatide, known to manage type 2 diabetes, as the first effective drug therapy for obstructive sleep apnea (OSA), a sleep-related disorder characterized by repeated episodes ...